peptide confessions

Semaglutide (Ozempic, Wegovy): Evidence and What Users Report

49 anonymous reports

Also known as:

semaozempicwegovyrybelsus

often mentioned with:

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist sold as Ozempic (type 2 diabetes injection), Wegovy (weight-management injection and pill) and Rybelsus (diabetes pill). It mimics the gut hormone GLP-1, slowing stomach emptying and reducing appetite. What is GLP-1? explains the hormone.

What the trials show

In STEP 1, adults with obesity lost about 15% of body weight on average over 68 weeks with Wegovy-strength semaglutide, vs about 2% with placebo. In the SURMOUNT-5 head-to-head trial, average loss was 13.7% with semaglutide vs 20.2% with tirzepatide at 72 weeks (Zepbound vs Wegovy).

In SELECT, 17,604 adults with overweight or obesity and existing heart disease (without diabetes) had a 20% lower risk of heart attack, stroke or cardiovascular death on semaglutide vs placebo. In the STEP 1 extension, people who stopped regained about two-thirds of the weight they had lost within a year.

Safety: gastrointestinal effects are the most common reason people stop. Labels warn about pancreatitis, gallbladder disease and thyroid C-cell tumours in rodents, and in 2025 the European Medicines Agency listed NAION, an optic-nerve condition, as a very rare side effect. Last reviewed: October 2026.

What semaglutide confessions describe

Regain after stopping is the most repeated story. One writer took it for 14 months and says they "gained it all back in 4" (#57); another quit after 11 months and 65 lbs and says the food noise came back within three weeks (#87).

Switching is the second theme. Several writers moved to tirzepatide or retatrutide after a stall, saying semaglutide made overeating feel miserable rather than removing hunger (#384, #194, #668). Others describe the full GI picture of nausea, vomiting, constipation and burping (#298), and one attributes major hair shedding to the rapid weight loss (#43).

These are anonymous personal accounts, not incidence data.

Anonymous semaglutide reports

If you have used semaglutide, including stopping or switching, submit what actually happened.

Submit yours

Community Q&A

How much weight do people lose on semaglutide?
In STEP 1, average loss was about 15% of body weight over 68 weeks vs about 2% with placebo. Individual results vary widely.
What happens when you stop semaglutide?
In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping. Regain is also the most common theme in confessions here.
Is semaglutide or tirzepatide better for weight loss?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced more average weight loss (20.2% vs 13.7%). Tolerability, coverage and medical history also matter.
Is this page a semaglutide dosing guide?
No. This is not a dosing recommendation. The site does not name or recommend suppliers.
What does semaglutide do to your pancreas?
It boosts glucose-dependent insulin release from the pancreas. The label warns about acute pancreatitis; stop and seek care for severe, persistent abdominal pain.
What organ is Ozempic hard on?
Label warnings cover the pancreas (pancreatitis), gallbladder (gallstones), kidneys (injury from dehydration after vomiting or diarrhea) and a boxed warning about thyroid C-cell tumours seen in rodents.
How does Ozempic affect A1C?
In the SUSTAIN 7 trial, semaglutide lowered HbA1c by 1.5 to 1.8 percentage points over 40 weeks in adults with type 2 diabetes.

Sources

  1. STEP 1 — Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021
  2. SURMOUNT-5 — Aronne et al., Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025
  3. SELECT — Lincoff et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023
  4. SUSTAIN 7 — Pratley et al., Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018
  5. Zepbound (tirzepatide) prescribing information — DailyMed (NLM)
  6. Wegovy (semaglutide) prescribing information — DailyMed (NLM)
  7. Ozempic (semaglutide) prescribing information — DailyMed (NLM)
  8. EMA PRAC meeting highlights, 2–5 June 2025 (semaglutide and NAION)

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.

the week's best confessions, in your inbox.